Esteban Velarde
Overview
Explore the profile of Esteban Velarde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Appidi T, China D, Stefan G, Moreau M, Mao S, Velarde E, et al.
Mol Cancer
. 2025 Mar;
24(1):68.
PMID: 40050802
Clinical cancer treatment modalities include radiation as one of the first-line therapies used for treating almost two-thirds of cancer patients. Combinational therapy for cancer is becoming extremely popular, with multiple...
2.
Slika H, Shahani A, Gattu K, Mundrathi V, Solan A, Gonzalez B, et al.
Mol Pharm
. 2024 Dec;
22(1):131-141.
PMID: 39666995
Glioblastoma multiforme is the most frequently diagnosed primary malignant brain tumor. Despite multimodal therapy with surgical resection, radiation therapy, and chemotherapy, recurrence of the tumor is almost always guaranteed due...
3.
Lam B, Kung Y, Lin J, Tseng S, Tu H, Huang C, et al.
J Clin Invest
. 2023 Nov;
134(1).
PMID: 37917174
Even with the prolific clinical use of next-generation cancer therapeutics, many tumors remain unresponsive or become refractory to therapy, creating a medical need. In cancer, DCs are indispensable for T...
4.
Lin B, Shin J, Jeffreys W, Wang N, Lukban C, Moorer M, et al.
JCI Insight
. 2022 Sep;
7(19).
PMID: 36099033
Gene mutations causing loss of dystrophin result in the severe muscle disease known as Duchenne muscular dystrophy (DMD). Despite efforts at genetic repair, DMD therapy remains largely palliative. Loss of...
5.
Liatsou I, Josefsson A, Yu J, Cortez A, Bastiaannet R, Velarde E, et al.
Int J Radiat Oncol Biol Phys
. 2022 Aug;
115(2):518-528.
PMID: 35926719
Purpose: We have determined the in vivo relative biological effectiveness (RBE) of an alpha-particle-emitting radiopharmaceutical therapeutic agent (Pb-labeled anti-HER2/neu antibody) for the bone marrow, a potentially dose-limiting normal tissue. Methods...
6.
Mishra A, Zennami K, Velarde E, Thorek D, Yegnasubramanian S, DeWeese T, et al.
Prostate
. 2021 May;
81(11):745-753.
PMID: 34032307
Background: Current preclinical models of metastatic prostate cancer (PCa) require sophisticated technologies and/or genetically engineered cells for the noninvasive monitoring of tumors in remote sites, such as bone. Recent developments...
7.
Chu C, Davis C, Lan X, Hienz R, Jablonska A, Thomas A, et al.
Int J Radiat Oncol Biol Phys
. 2020 May;
108(3):745-757.
PMID: 32470502
Purpose: Improved efficacy of anticancer therapy and a growing pool of survivors give rise to a question about their quality of life and return to premorbid status. Radiation is effective...
8.
Oei A, Korangath P, Mulka K, Helenius M, Coulter J, Stewart J, et al.
Int J Hyperthermia
. 2019 Dec;
36(sup1):47-63.
PMID: 31795835
Enhancing immune responses in triple negative breast cancers (TNBCs) remains a challenge. Our study aimed to determine whether magnetic iron oxide nanoparticle (MION) hyperthermia (HT) can enhance abscopal effects with...
9.
Woodard L, Dennis C, Borchers J, Attaluri A, Velarde E, Dawidczyk C, et al.
Sci Rep
. 2018 Aug;
8(1):12706.
PMID: 30139940
Magnetic iron oxide nanoparticles (MIONs) have established a niche as a nanomedicine platform for diagnosis and therapy, but they present a challenging surface for ligand functionalization which limits their applications....
10.
Piotrowski A, Nirschl T, Velarde E, Blosser L, Ganguly S, Burns K, et al.
Oncoimmunology
. 2018 Jun;
7(7):e1445951.
PMID: 29900062
Severe radiation-related lymphopenia is common and associated with decreased survival in patients with several solid tumors. As the mechanisms underlying systemic lymphopenia are poorly understood, we developed an animal model...